99 related articles for article (PubMed ID: 2578698)
21. Treatment of severe pertussis by administration of specific gamma globulin with high titers anti-toxin antibody.
Ichimaru T; Ohara Y; Hojo M; Miyazaki S; Harano K; Totoki T
Acta Paediatr; 1993 Dec; 82(12):1076-8. PubMed ID: 7512392
[TBL] [Abstract][Full Text] [Related]
22. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
23. [Antibiotics in association with gamma-globulin in experimental pertussis infection of chick embryos].
TEBIAKINA AE; CHAIKOVSKAIA SM
Antibiotiki; 1961 Sep; 6():53-8. PubMed ID: 13920050
[No Abstract] [Full Text] [Related]
24. The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity.
Wolfe DN; Goebel EM; Bjornstad ON; Restif O; Harvill ET
Infect Immun; 2007 Oct; 75(10):4972-9. PubMed ID: 17698566
[TBL] [Abstract][Full Text] [Related]
25. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.
Relyveld E; Oato NH; Guérin N; Coursaget P; Huet M; Gupta RK
Vaccine; 1991 Nov; 9(11):843-50. PubMed ID: 1759508
[TBL] [Abstract][Full Text] [Related]
26. [STUDY OF THE ACTION OF ANTI-PERTUSSIS GAMMA GLOBULIN ON THE FORMATION OF CELLULAR REACTIONS IN EXPERIMENTAL PERTUSSIS INFECTION].
SUMAROKOV AA; KULIKOVA IuM
Zh Mikrobiol Epidemiol Immunobiol; 1964 Apr; 41():13-7. PubMed ID: 14221631
[No Abstract] [Full Text] [Related]
27. Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin.
Halperin SA; Issekutz TB; Kasina A
J Infect Dis; 1991 Feb; 163(2):355-61. PubMed ID: 1703192
[TBL] [Abstract][Full Text] [Related]
28. Transplacental and transcolostral immunity to pertussis in a mouse model using acellular pertussis vaccine.
Oda M; Izumiya K; Sato Y; Hirayama M
J Infect Dis; 1983 Jul; 148(1):138-45. PubMed ID: 6309992
[TBL] [Abstract][Full Text] [Related]
29. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1347-51. PubMed ID: 2304902
[TBL] [Abstract][Full Text] [Related]
30. Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.
Aase A; Herstad TK; Merino S; Brandsdal KT; Berdal BP; Aleksandersen EM; Aaberge IS
Clin Vaccine Immunol; 2007 Jul; 14(7):855-62. PubMed ID: 17507542
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
[TBL] [Abstract][Full Text] [Related]
32. Passive acquisition of protective antibodies reactive with Bordetella pertussis in newborns via placental transfer and breast-feeding.
Quinello C; Quintilio W; Carneiro-Sampaio M; Palmeira P
Scand J Immunol; 2010 Jul; 72(1):66-73. PubMed ID: 20591078
[TBL] [Abstract][Full Text] [Related]
33. Protection against intranasal infection of mice with Bordetella pertussis.
Robinson A; Ashworth LA; Baskerville A; Irons LI
Dev Biol Stand; 1985; 61():165-72. PubMed ID: 2872102
[TBL] [Abstract][Full Text] [Related]
34. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of serological tests for diagnosis of Bordetella pertussis infection in adolescents and adults.
Miyashita N; Kawai Y; Yamaguchi T; Ouchi K
Respirology; 2011 Nov; 16(8):1189-95. PubMed ID: 21790881
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
[TBL] [Abstract][Full Text] [Related]
37. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
[TBL] [Abstract][Full Text] [Related]
38. Characterization of mutant strains producing pertussis toxin cross reacting materials.
Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection.
Watanabe M; Komatsu E; Sato T; Nagai M
FEMS Immunol Med Microbiol; 2002 Jul; 33(3):219-25. PubMed ID: 12110485
[TBL] [Abstract][Full Text] [Related]
40. Assessment of serum anti-Bordetella pertussis antibody titers among medical staff members.
Higa F; Haranaga S; Tateyama M; Hibiya K; Yamashiro T; Nakamatsu M; Tomoyose T; Nagahama M; Okamura T; Owan T; Kuda T; Kinjo F; Fujita J
Jpn J Infect Dis; 2008 Sep; 61(5):371-4. PubMed ID: 18806344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
